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Abstract--Triggered by agonist binding to cell surface receptors, the heterotrimeric G proteins dissociate into t~ 
and 13y subunits, each activating distinct second messenger pathways. Peptides from the primary sequences of recep- 
tors, G proteins, and effectors have been used to study the molecular interactions between these proteins. Receptor- 
derived peptides from the second, third and fourth intracellular loops and certain naturally occurring peptides antag- 
onize G protein interactions and can directly activate G protein. These peptides bind to G protein sites that include 
the N and C terminal regions of the ct subunit and a yet to be identified region of the [3 subunit. Peptides have also 
been useful in characterizing G protein-effector interactions. The identification of the contact sites between proteins 
involved in G protein signal transduction should aid in the development of non-peptide mimetic therapeutics which 
could specifically modify G protein-mediated cellular responses. 
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INTRODUCTION 
This review will focus on the use of peptides (nat- 
urally occurring, G protein-derived, or receptor- 
derived) to study receptor-G protein coupling and 
G protein activation. Peptides have been used to 
address a number of questions regarding receptor- 
G protein interactions including: which regions of 
receptors come in contact with the G protein; 
which residues in receptor are responsible for G 
protein activation; and which regions of the G 
protein are responsible for effector activation. The 
sites of contact between these proteins could pro- 
vide targets for therapeutic drug design. 
Most of the peptides used in such studies have 
been synthesized corresponding to specific 
sequences in the protein of interest (rational 
design). However, other peptide sources (includ- 
ing synthetic libraries or phage display libraries) 
could be potentially useful in the identification of 
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peptides which selectively target the proteins 
involved in G protein signal transduction. 
MAPPING THE RECEPTOR-G PROTEIN 
INTERFACE 
G proteins are heterotrimeric proteins com- 
posed of tx, [3, and y subunits. Current modeling of 
the receptor-G protein interaction suggests that 
receptors bind to both the N and C terminal 
regions of the tx subunit [1]. Data in support of 
this model include the ability of mutations in the 
C terminus of the ~ subunit [2, 3] and covalent 
modification of the C terminus of t~ i by pertussis 
toxin to block receptor-G protein interactions [4]. 
Also, as will be discussed, peptides derived from 
the N and C terminus of the o~ subunit block 
receptor-G protein interactions [5]. Recent evi- 
dence suggests that the ~y subunit complex may 
also be important in coupling receptors to G pro- 
teins [6-10]. However, residues in either [3 or y 
subunits that participate in G protein coupling to 
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specific G protein coupled receptors (GPCR) 
remain to be identified. 
G protein-derived peptides 
To explore the molecular interactions between 
receptors and G proteins, synthetic peptides corre- 
sponding to G protein sequences were examined 
for their ability to block receptor-G protein coup- 
ling. This approach is based on the idea that a 
peptide derived from a region of the G protein that 
is involved in receptor binding will bind to the 
receptor and compete with G protein binding. In 
1988, Hamm et al. showed that peptides from the 
extreme N terminus (residues 8-23) and C termi- 
nus (residues 311-329 and 340-350) of the alpha 
subunit of the retinal rod G protein, transdutin 
(Gv), could block binding of Gv to rhodopsin. 
Subsequently, Palm et al. showed that a peptide 
derived from the corresponding C-terminal region 
of the t~ s subunit (residues 379-394) blocked 13~- 
.adrenergic receptor (I3~-AR) mediated activation 
of adenylyl cyclase [11]. These data were consis- 
tent with earlier mutagenesis which showed that 
replacement of a C-terminal Arg by a Pro in ct s 
blocked receptor-G protein interactions [3], and 
truncation of the C-terminal 5 amino acids of 
Scgl (the ct subunit involved in yeast mating) 
blocked pheromone receptor-Scgl interactions 
[2]. Also, chimaeric [ff, q][3~i2 subunits containing 
only the C-terminal 3 amino acids of o~i2 signal 
through cti2 coupled receptors [12]. 
A more conventional use of synthetic peptides 
has been to generate antibodies against G protein- 
derived peptides to examine receptor-G protein 
interactions. Antibodies raised against C terminal 
peptides from alpha subunits block receptor-G 
protein interactions [13]. Using antibodies gener- 
ated to decapeptides from the C-termini of various 
G protein subtypes, Simonds et al. showed that 
the ~2-adrenergic receptor ((Xz-AR) mediates inhi- 
bition of adenylyl cyclase in platelet membranes 
through Gi2 exclusively [14]. Using similar tech- 
niques, Gerhardt and Neubig showed that o~-AR, 
when transfected into CHO-K1 cells, could signal 
through either G~2 or G~3 to mediate adenylyl 
cyclase inhibition [15]. Also Gutowski et al. used 
peptide-specific C-terminal antibodies against Gq 
to show that angiotensin (in neuroblastoma cells) 
and bradykinin (in rat liver cells) signal through 
that G protein to stimulate PIP 2 hydrolysis [16]. 
The use of peptide-derived antibodies in such 
studies has been reviewed recently [ 17]. 
Receptor-derived peptides 
Rhodopsin, ~ adrenergic, 13 adrenergic, and 
muscarinic receptors are members of a large 
receptor family that couples to various signal 
transduction pathways through G proteins. 
Sequence analysis predicts that these GPCR are 
structurally similar, consisting of seven membrane 
spanning regions, three cytoplasmic loops and 
an intracellular C-terminus [18]. Early studies 
employing site-directed mutagenesis and chi- 
maeric receptor constructs have implicated the 
third cytoplasmic loop and possibly the second 
cytoplasmic loop and C-terminal tail in coupling 
these receptors to G proteins [ 19-25]. 
Receptor-derived peptides have proven useful 
in further examining the regions of GPCRs 
involved in receptor-G protein coupling. In 1989 
Konig et al. reported that peptides derived from 
sequences in rhodopsin could block rhodopsin-G x 
interactions [26]. Eleven peptides were synthe- 
sized comprising all putative aqueous-exposed 
regions of rhodopsin. Of these only three peptides, 
those corresponding to the second (i2) and third 
(i3) intracellular loops and the N-terminal region 
of the cytoplasmic tail (i4N), could block GT bind- 
ing to photoactivated rhodopsin. The Hill coeffi- 
cients for competitive binding to GT ranged from 
1.8 to 2.4. Interestingly, combining any two of the 
active peptides reduced their Ics0 30-fold. 
Addition of the third active peptide further 
reduced the ICs0 (two-fold) to a level within one 
order of magnitude of the affinity of intact 
rhodopsin for transducin. Previously, Franke et al. 
showed that replacement or deletion of an i2 
region of rhodopsin or deletion of an i3 region of 
rhodopsin blocked rhodopsin-mediated G protein 
activation [20, 22]. The peptide data confirm and 
extend this mutagenesis study by providing evi- 
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dence that the i2, i3 and i4N regions of rhodopsin 
directly interact with G protein. 
Shortly thereafter, Palm et al. used ~l-adrener- 
gic receptor-derived peptides to examine G pro- 
tein signal transduction. Their studies indicated 
that peptides derived from the i2, C-terminal part 
of i3 (i3C) and, to a lesser extent, the first intra- 
cellular loop (il) all modified receptor-mediated 
adenylyl cyclase activity in turkey erythrocyte 
membranes [27]. The authors later reported that 
these peptides competed synergistically with the 
~l-receptor for G protein binding [28]. In addition, 
we have shown that peptides from the i2, N-termi- 
nal i3 (i3N) and i3C regions of the t~2-AR could 
block ct2-AR-G protein interactions [29, 30]. 
Similar methods have been used to determine the 
regions involved in G protein coupling to other 
GPCRs including the 132-adrenergic [31], the D2 
dopamine [32], and the N-formyl peptide receptor 
[33]. The ability of peptides derived from the i2, 
i3 and i4 regions of various GPCRs to block 
receptor-G protein interactions indicates that these 
specific receptor regions are involved in coupling 
receptors to G protein. However, it is not clear 
from these studies whether these peptides block 
coupling at the level of the receptor or the G pro- 
tein. 
G PROTEIN ACTIVATOR PEPTIDES 
Ligand binding to a GPCR causes a conforma- 
tional change in the receptor which activates G 
protein by stimulating the exchange of GDP for 
GTP. The activated GTP-bound G protein is then 
thought to dissociate into t~-GTP and ~7 subunits, 
both of which interact with specific effector sys- 
tems to propagate second messenger signals. 
Since ~ subunits have an intrinsic GTPase, recep- 
tor-mediated G protein activation can be mea- 
sured by an increase in the apparent rate of GTP 
hydrolysis. 
Naturally occurring G protein activators 
In 1986 Higashijima et al. reported the first 
evidence that short peptides could directly acti- 
vate G protein. The authors demonstrated that a 
wasp venom tetradecapeptide, mastoparan, in- 
duced histamine release from mast cells by direct 
G protein activation [34]. The effects of 
mastoparan were similar to receptor-mediated G 
protein activation in that mastoparan (i) enhanced 
GTPase activity at submicromolar Mg2÷; (ii) was 
more effective when the G protein was reconsti- 
tuted in phospholipid vesicles; and (iii) had no 
effect after pertussis toxin ribosylation of G pro- 
teins [34]. These data support the concept that 
mastoparan, a cationic amphiphilic tetradecapep- 
tide, binds to and stimulates G proteins in a man- 
ner similar to that of agonist liganded GPCRs. 
Since the discovery of mastoparan a number of 
naturally occurring peptides and GPCR derived 
peptides have been shown to bind to and stimulate 
G proteins directly. Mast cell degranulating pep- 
tide (MCD, an amphiphilic 22 amino acid peptide 
derived from honey bee venom) also induces hist- 
amine release from mast cells and directly acti- 
vates G protein [35, 36]. A similar mechanism has 
been proposed for the venom peptide melittin 
[37]. Other peptides including substance P [38, 
39], bradykinin [40], dynorphin [37] and 
angiotensin II [37] have been shown to activate G 
proteins directly with increases in GTPase activity 
ranging from two- to three-fold for 100 ktM 
dynorphin to four- to seven-fold for 100 ~tM 
angiotensin II. 
Synthetic (receptor-derived) G protein activators 
The first evidence that receptor-derived pep- 
tides could directly stimulate G proteins was 
reported by Palm et al. in 1989. The authors 
examined the ability of I~I-AR derived peptides to 
attenuate receptor-mediated adenylyl cyclase and 
noted that one peptide derived from the i3C 
region stimulated adenylyl cyclase in the absence 
of agonist [27]. These data suggested that this 
peptide can assume the conformation of an acti- 
vated receptor thereby activating Gs protein signal 
transduction in a hormone-independent manner. 
Following this observation, Okamoto and 
Nishimoto examined the capacity of peptides 
derived from the cytoplasmic domain of the 
insulin-like growth factor-II (IGF-II) receptor to 
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directly activate G proteins. One tetradecapeptide 
(peptide 14) activated Gi2 GTPase in a manner 
reminiscent of receptor-mediated G protein acti- 
vation. An antibody raised against this peptide 
fully attenuated IGF-II receptor-mediated G pro- 
tein activation, which further indicated that this 
region of the receptor was critical for IGF-II sig- 
nalling [41-43]. Later, Dalman and Neubig 
showed that trideca- and tetradecapeptides from 
the i3N and i3C regions of the c~2-AR directly 
stimulated Go/G~ protein GTPase in phospholipid 
vesicles [29, 44]. Okamoto and Nishimoto [45] 
and Ikezu et al. [46] also found that ot2-AR i2 and 
i3N, as well as i3C derived peptides all directly 
activated G~ and Go proteins. The list of peptides 
which directly activate G proteins has grown to 
include peptides derived from the M4 muscarinic 
receptor (i2 and i3C) [45], the ~2-AR (i3N and 
i3C) [31, 47] and the D2-dopamine receptor (i3N) 
[481. 
Structural relationships of  activator peptides 
Secondary structure may be an important deter- 
minant for peptide activity. The membrane and G 
protein bound conformations of mastoparan are 
amphiphilic alpha helices [49, 50]. Higashijima 
observed a correlation between the helical content 
of several mastoparan analogs and their ability to 
stimulate purified G proteins [37]. Other G pro- 
tein activators including MCD and the i3N I]2-AR 
peptide [51] also form amphiphilic alpha helices. 
These data are consistent with the idea that i3N 
and/or i3C regions of the 13 adrenergic receptors 
form ~ helices within the tertiary structure of the 
protein [52]. However, the specific amino acid 
residues within the helices responsible for activa- 
tion have yet to be identified. Higashijima et al. 
reported that the lysine residues within the helix 
of mastoparan were critical for activity and sug- 
gested that these basic residues bind to the G pro- 
tein [37]. However, a study with mutated 132-ARs 
suggests that the hydrophobic residues (not the 
basic residues) within the ~ helix of the i3N 
region are important in G protein activation [53]. 
Also, the ability of peptides to form an ~ helix is 
neither necessary nor sufficient for G protein acti- 
vation. Oppi et al. demonstrated that of four MP 
analogs which formed ~ helices only two were 
active [54]. Voss et al. found no correlation 
between the helical content of peptides derived 
from dopamine receptor (D 1 and D2) and [3~-AR 
and their ability to stimulate GJG~ or G~ proteins 
[48]. 
Okamoto and Nishimoto suggest that the pri- 
mary amino acid sequence may be more important 
than secondary peptide structure in determining 
peptide activity [42]. They postulated that activa- 
tor sequences fit the three following criteria: (i) 
10-26 residues in length; (ii) two basic residues 
near the N-terminus; and (iii) either a BBXB or 
BBXXB (B = basic AA) sequence at the C-termi- 
nus. These requirements were defined by activator 
peptides derived from both the IGF-II receptor 
(peptide 14) and the 132-AR (i3C) [41, 47]. The 
authors found regions in the 0~2-AR and M4AR 
that fitted these criteria and synthesized the corre- 
sponding peptides which could directly activate 
Go and Gi proteins [45]. The i3C region of the ~2- 
AR also fits these criteria with a slight modifica- 
tion of rule (iii) to include a C-terminal aromatic 
residue [46]. Although these sequence criteria can 
be useful in defining potential G protein activating 
regions within receptors, not all G protein activa- 
tors fit such requirements. Notably, the naturally 
occurring activators mastoparan, SP, bradykinin, 
MCD, melittin and bombolitin fit only the first 
(10-26 residues in length) of three proposed cri- 
teria for G protein activator sequences. Of the 
receptor-derived activators the i3N 132-AR peptide 
[31] fits only the first criterion, whereas the i3C 
~2-AR peptide [31] and i3c 131-AR peptide [27] fit 
the first and second criteria and the i3N D2 peptide 
[48] fits the first and third criteria. 
In general, the G protein activator peptides are 
short cationic peptides, however, their sequence 
patterns, hydrophobicity, amphiphilicity and heli- 
cal content vary. These data are consistent with 
the notion that the active sequences may bind to 
different regions on G protein. 
Peptide modifications 
High concentrations of some of these peptides 
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are required to activate G proteins. Most of the 
activator peptides have ECsoS in the 10-30 t.tM 
range, although a few (mastoparan, MCD, an i3C 
M4 peptide, and a i3C tx2-AR peptide) have ECs0S 
around 300 nM. A number of studies have indi- 
cated that increasing the hydrophobicity of activa- 
tor peptides can increase their potency. Okamoto 
et al. observed that addition of an 11 residue 
hydrophobic segment of the IGFII transmembrane 
domain to the IGFII activator peptide (peptide 14) 
increased the potency of the activator peptide over 
300-fold [41]. Similarly, Nishimoto et al. reported 
that addition of a small hydrophobic transmem- 
brane domain of Alzheimer amyloid protein (APP) 
to the APP G protein activator peptide increased 
its potency 10-20-fold [55]. Also, we have 
observed that the attachment of a hydrophobic dia- 
zopyruvoyl cross-linking agent to the i3C ot2-AR 
peptide enhances the potency of this peptide 15- 
fold [56]. The addition of a hydrophobic tail may 
anchor these activator peptides into the phospho- 
lipid meiilbranes and stabilize their active confor- 
mation. Interestingly, both the extreme N- and C- 
terminals of the t~ subunit are hydrophobic. Binding 
to these regions could account for the enhanced 
affinity of the hydrophobic peptide analogs. 
As mentioned previously, inclusion of two or 
more peptides from rhodopsin or the [32-AR syner- 
gistically enhanced the potency of these peptides 
to block receptor-G protein interactions. Recently, 
Wade et al. have shown that a heterodimer of two 
activator peptides from the i3N and i3C regions of 
the ~2-AR is 10-fold more potent in activating G 
proteins than either monomer peptide [30]. The 
possibility exists that varying connector chain 
lengths of such heterodimers may further enhance 
the potency of these peptides. 
Although modifications of the G activator pep- 
tides have enhanced their potency, they have not 
enhanced their efficacy. Mastoparan appears to be 
the most efficacious peptide with seven- to 20- 
fold increases in Go/G~ GTPase and two- to four- 
fold increases in Gs GTPase [34]. Mastoparan 
appears to act as a full agonist in G i stimulation, 
but a partial agonist in Gs stimulation. Most recep- 
tor-derived peptides increase GTPase two- to five- 
fold, which is consistent with the extent of recep- 
tor-mediated GTPase in reconstituted systems 
[57-59]. However, we have shown that the i3C 
peptide from the ct2-AR (which stimulates a two- 
fold increase in Gi GTPase) acts as a partial G~ 
agonist and thus blocks ct2-AR agonist promoted 
GTPase in platelet membranes and mastoparan 
promoted GTPase in lipid vesicles [29, 30, 44]. 
Peptide specificity 
Lack of specificity for certain G protein sub- 
types is a major problem associated with the use 
of these small peptides. The G protein activator 
derived from IGF-II receptor (peptide 14) is the 
most selective of the activator peptides. Peptide 
14 preferentially activated the inhibitory G pro- 
teins (Gi2>Gil = Gi3) and to a lesser extent the 
closely related Go protein. Peptide 14 had no 
effect on either the stimulatory G protein (Gs), or 
two members of the low molecular weight G pro- 
teins, c-Ki-ras p21 and smg p25A [41]. As previ- 
ously mentioned, mastoparan is selective for the 
Gi and Go proteins but also stimulates Gs proteins 
[34]. Peptides derived from the ~2-AR [31] and 
the ct2-AR [46] were slightly more selective acti- 
vators of Gs than G i ([3cAR) o r  G i than G~ (or 2- 
AR). The identification of the peptide binding 
sites may aid in the rational design of more sub- 
type selective G protein activators. 
Peptide binding sites 
Mastoparan appears to bind to a site in the N- 
terminal [60] and/or C-terminal region [61] of the 
tx subunit. These regions are closely associated in 
the tertiary structure of the G protein [62]. The 
ability of pertussis toxin to attenuate GTPase 
stimulation by the IGF-II peptide 14 [41] and the 
i3N ct2-AR (unpublished observations, Taylor and 
Neubig) suggests that these peptides may bind in 
the C-terminal region of the ct subunit. We 
recently found that the activator peptide i3C from 
the ~2-AR binds specifically to both the N-termi- 
nal region in the t~ subunit and a site on the 13 sub- 
unit [56, 63]. Also, the I]~/ subunit complex is 
required for i3C stimulated G protein activation 
[56]. Phillips and Cerione have determined that an 
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Fig. 1. Molecular interactions in G protein-mediated signal transduction. Mutagenesis and synthetic peptide studies 
provide evidence for a model of the sites of G protein interaction with receptors and effectors. The proposed second 
(i2), third (i3) and fourth (i4) intracellular loops of GPCRs are involved in coupling to G protein. The ovals repre- 
sent putative sites of interaction of these regions of the receptor with G protein. Evidence in support of this model 
(see text) includes: (i) pertussis toxin blockade of GTPase stimulation by an i3N a2-AR peptide; (ii) cross-linking of 
an i3C u2-AR peptide to both the N-terminal region of the ct subunit and a site on the 13 subunit; and (iii) binding of 
an i4 rhodopsin-derived peptide to a site on transducin 137 subunit. The dashed oval surrounding the i2 peptide indi- 
cates that this binding site is less well defined. Peptide studies have also identified an effector (PDE) binding site on 
t~r (aa 293-314) as well as the corresponding site on the PDE7 subunit to which it binds (aa 24-45). A similar 
region on the tz S (aa 236-356) has been implicated in binding adenylyl cyclase. The 137 subunit interacts with 
phospolipase C 13 (PLC13) and the 13-adrenergic receptor kinase (13ARK), but the amino acids involved have yet to be 
identified. Many G protein-effector interactions (and possibly other receptor-G protein interactions) will likely be 
identified in the near future. 
i4 rhodopsin-derived peptide also binds to a site 
on the 97 subunit [6]. These data are consistent 
with recent findings which suggest that GPCRs 
bind to the 97 subunit complex [6, 9, 64, 65] and 
signal through G proteins of  unique 97 subunit 
composition [7, 8]. Thus it appears that specificity 
of  receptor-effector coupling in cells does not 
reside in the t~ subunit alone, but involves recep- 
tor recognition of  137 subunits as well. Based on 
these data, a hypothetical organization of  the 
receptor-derived peptide binding sites on G pro- 
tein is shown in Fig. 1. Future studies to address 
the specific binding sites of  such peptides should 
be useful both in mapping the receptor-G protein 
interface and in developing more potent and selec- 
tive G protein activators. 
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EFFECTOR ACTIVATING PEPTIDES 
Most recently, peptides corresponding to G 
protein sequences were synthesized to study G 
protein-effector interactions. The regions that 
mediate adenylyl cyclase activation by t~s have 
been deduced from t~/~ s chimaera [66-68]. These 
studies indicated that four clusters of native cq 
residues within a 121 amino acid region (aa 
236-356) were required to observe functional 
coupling to adenylyl cyclase. In 1992 Rarick et al. 
showed that a peptide derived from a similar 
region of the cz subunit of GT (aa 293-314) 
directly activated cGMP-phosphodiesterase (PDE) 
[69]. Later studies, using a fluorescent probe, 
determined the specific residues within PDE (aa 
24 45) which bind the ct, r derived activator 
sequence [70]. These studies were confirmed by 
evidence that a peptide derived from PDE 
residues 24-45 cross-linked to a site on ~r within 
residues 306-310 [71]. Others have utilized pep- 
tides derived from low molecular weight G pro- 
teins to identify down-stream effectors [72-74], 
however the details of these studies are beyond 
the scope of this review. 
CONCLUSIONS AND FUTURE DIRECTIONS 
Peptides can be used to screen large areas of 
proteins to determine the critical regions involved 
in their protein-protein interactions. Clearly, the 
use of peptides has proven effective in determining 
the specific regions involved in receptor-G protein 
and certain G protein-effector interactions. Such 
data can be used to develop a structural map of the 
interactions between the major proteins in GPCR 
signal transduction (Fig. 1). A number of peptide 
studies suggest that the proposed second, third and 
fourth intracellular loops of GPCRs couple to G 
protein. The specific residues in the G protein to 
which these regions bind are yet to be determined, 
although both the N and C-terminus of the t~ sub- 
unit and a site on the 13 subunit have been impli- 
cated in receptor binding. The identification of the 
mutual contact sites between such proteins should 
aid in the development of therapeutic agents which 
could specifically target G protein signal transduc- 
tion at multiple levels. 
In light of recent evidence that certain diseases 
such as hyperthyroidism [75] and familial preco- 
cious puberty [76] may result from aberrant recep- 
tor-mediated G protein activation, the potential for 
G protein modulating peptides as models for ther- 
apeutic agents is clear. However, peptides them- 
selves are unlikely to be suitable for administra- 
tion as therapy. Two possible avenues could be 
explored to overcome potential problems of pepti- 
dases and the inability of these peptides to tra- 
verse target cell membranes. One area of interest 
is the growing field of peptidomimetics whereby 
non-peptide analogs with similar structures can be 
synthesized and tested for their abilities to mimic 
peptide activities [77]. The ability to place confor- 
mational constraints on non-peptide analogs can 
actually improve potency and selectivity as has 
been observed for certain opiate peptide antago- 
nist analogs [78]. Gene therapy is another poten- 
tial mechanism which can bypass problems asso- 
ciated with targeting these peptides to their sites 
of action [79]. Luttrell et al. employed a mini- 
gene strategy to show that expression of the am- 
AR i3 loop in human embryonic kidney cells 
inhibited t~ia and CZic but not M~ muscarinic or DiA 
domamine receptor-mediated signal transduction 
[80]. Both approaches should be useful in the 
future development of therapeutic strategies to tar- 
get the receptor-G protein interface. 
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